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The gut microbial population is significantly compromised in high fat feeding. These 
changes are associated with obesity and type 2 diabetes (T2D). Fermentation of non-
digestible carbohydrates and fiber from plant food sources are suggested to prevent gut 
dysbiosis due to high fat feeding. Various parts of mango have been studied for their anti-
obesogenic, immunomodulatory and gastroprotective abilities. This study investigated the 
effects of 12-week freeze-dried mango pulp supplementation on the gut microbiota and 
its impact on body composition, glucose homeostasis and inflammatory markers in 
C57BL/6 mice fed a high fat (HF) diet. Male C57BL/6 mice were randomly assigned to 4 
dietary treatment groups: Control (AIN-93M, 10% kcal from fat), HF (60% kcal from 
fat), and HF+1% or 10% mango. Cecal sample analyses by 16S rDNA sequencing show 
that HF feeding resulted in a significant loss of bacteria, most notably Bifidobacteria and 
Akkermansia while mango supplementation prevented the loss of these bacteria in a 
dose-dependent manner similar to control. Mango supplementation did not reduce body 
weight or fasting blood glucose. Plasma lipids were elevated with HF feeding compared 
to control, with both mango doses lowering plasma triglyceride. The HF+10% mango 
significantly lowered plasma non-esterified fatty acids but increased plasma total 
cholesterol. In comparison to the HF group, a dose-dependent increase in microbial 
fermentation was observed with mango supplementation, as evident in increased fecal 
and cecal acetic and butyric acid but not propionic acid. Furthermore, mango 
supplementation modulated gut inflammation, as observed with an increase in ileal and 
colonic IL-10 gene expression compared to the HF group. These results demonstrate that 
mango supplementation in high fat feeding modulated some of the adverse effects that 
accompanies high fat diet-induced obesity.
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The incidence of obesity is reaching pandemic proportions globally and in the 
United States [1, 2]. Apart from genetic predisposition, obesity results from a long-term 
positive imbalance between energy intake and expenditure which may be regulated by 
multiple pathways. Importantly, the evolutionary change in our food behavior has 
introduced a diet rich in fat and refined sugars which are associated with increased 
incidence of various chronic diseases including obesity [3]. High fat diet-induced obesity 
has been reported to be associated with insulin resistance and type 2 diabetes (T2D) 
characterized by a state of inflammation and increased susceptibility to infection due to 
the malfunction of the immune system [4]. Furthermore, obesity induced by a high fat 
diet results in dyslipidemia which is a significant risk factor for cardiovascular diseases 
[5]. Therefore, these debilitating impacts of obesity make it an epidemic which is an 
unprecedented challenge to public health and civilized societies [6]. 
 The human intestine serves as an environment for various bacteria and some 
archaea species living in a commensal relationship with the host [7, 8]. The gut microbial 
population has been reported to have a role in the maintenance of host’s immune 
response and also in digestion, absorption and metabolism of nutrients [7, 9]. 
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 Through the hydrolysis and fermentation of dietary polysaccharides that the host cannot 
otherwise digest, the gut microbiota may increase host energy harvest up to ~150 kcal 
[10]. The undigested portion of food moves into the colon in humans or cecum in mice 
where it is fermented predominantly into short chain fatty acids (SCFA) [11]. SCFA 
resulting from microbial fermentation is vital for the maintenance of the colonic epithelial 
cells’ integrity and may also be absorbed in the colon to impact liver and adipocyte 
metabolism [12, 13]. Moreover, SCFA have been shown to play a role in pancreatic 
insulin secretion by stimulating incretin production in the small intestine via the receptor 
GPR43 [14]. Importantly, the release of incretin is known to be responsible for 50-70%  
of insulin’s postprandial response to glucose [15]. Thus, these reports show that the gut 
microbiota directly and indirectly influences the host metabolism.   
Accumulating evidence has established that changes in the composition of the gut 
microbiota due to high-fat feeding play a significant role in obesity, insulin sensitivity, 
and obesity-associated inflammation characterized by an imbalance in pro-inflammatory 
and anti-inflammatory immune response [16, 17]. Cani and colleagues showed that high 
fat feeding in mice resulted in the dysbiosis of cecal microbiota compared to mice on a 
control diet, accompanied with increased body weight, fat accumulation, glucose 
intolerance and low grade inflammation [18]. Therefore, preserving the balance of the gut 
microbiota by feeding the commensal bacteria may help reduce the incidence of obesity 
and its detrimental outcomes [19].  
There have been reports suggesting that the gut microbial population can be 
effectively preserved, manipulated or regulated through good quality dietary patterns 
[20]. Dietary food components believed to play a role in the preservation of the gut 
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microbiota include polyphenols, fiber and non-digestible carbohydrates [21]. These food 
components are known as promoting factors for growth and survival of the beneficial gut 
bacteria [21]. These reports suggest that foods high in fiber and polyphenols may help 
maintain the balance of the intestinal microbiota and thus, reducing the incidence of 
chronic diseases like obesity and T2D. This is important since gut microbial dysbiosis by 
high fat diets encourages colonization of the gut by pathogens, impairs the intestinal 
epithelial barrier, thus promoting the passage of bacteria and their products such as 
lipopolysaccharide into the blood, which are initiating factors of obesity and its 
comorbidities [22].   One of such foods rich in fiber and polyphenols is mango [23]. 
Mango (Mangifera indica), a popular tropical fruit, has been reported to possess a 
variety of therapeutic effects that are often dependent on the part of the plant used. 
Studies have indicated that polyphenolic extracts from various mango parts have 
antioxidant, antidiabetic, immunomodulatory and gastroprotective activities [24]. 
Moreover, recent studies involving high-fat feeding indicate that supplementation with 
freeze-dried mango pulp modulates blood glucose and reduces adiposity without a 
negative impact on skeletal health unlike the widely-prescribed glucose-lowering 
medication, rosiglitazone [25, 26]. Depending on the variety, mango pulp has a total fiber 
content ranging between 1.3 – 3.8 g/100g, with  about 50% soluble fiber [27]  which may 
be substantially available to the gut bacteria for fermentation. Observations from these 
previous studies strongly suggest that mango is a functional food that may be beneficial 
in supplying nutrients to maintain a healthy living of the gut bacteria and the host. 
 Since the gut bacteria requires fiber, non-digestible carbohydrates and 
polyphenols as growth substrates which help maintain a balance in the gut microflora, our 
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current knowledge is lacking in the impact of mango on maintaining the balance of the 
gut microbiota in the event of a high-fat diet challenge which results in dysbiosis.  
Therefore, the purpose of this study is to determine the effects of freeze-dried mango 
pulp on the gut microbiota and its impact on body composition, blood glucose, 
inflammatory markers and gut integrity in mice fed a high fat diet. The hypothesis of this 
study is that mango supplementation will preserve the balance of the gut microbiota 
while maintaining blood glucose and body fat composition in C57BL/6 mice fed high fat 
diet. Apart from contributing to the scientific literature available on mango, this study 
will provide novel evidence on the possible effects of mango fruit in preventing gut 
dysbiosis with possible corresponding impacts on glucose homeostasis and body 
composition. The specific aims of the study are to investigate: 
1. The effects of dietary mango supplementation on cecal microbial population at 
the genus level. 
Working hypothesis: Mango supplementation will preserve the balance of the 
cecal microbiota by preventing the loss of beneficial bacteria in the gut which is 
usually associated with high-fat feeding. 
2. The impact of mango supplementation on body composition, blood glucose and 
plasma lipids in C57BL/6 mice fed a high-fat diet 
 Working hypothesis:  Mango supplementation will modulate body composition 




3. The impact of mango on cecal and fecal content of short chain fatty acids, and 
GPR43 (SCFA receptor) expression in the ileum and colon mucosa of C57BL/6 
mice fed a high-fat diet. 
 Working hypothesis:  Mango supplementation will significantly increase short 
chain fatty acid production, with a subsequent increased expression of their 
receptor, GPR43 in C57BL/6 mice fed a high-fat diet. This will indicate a gut 
protective effect of mango via SCFA-induced stimulation of GPR43 which is 
known to mediate gut inflammatory activities and incretin secretion. 
4. The effects of mango on anti-inflammatory [i.e. interleukin (IL)-10] and pro-
inflammatory (IL-1β, IL-6) cytokine expression in the ileum, colon and plasma of 
C57BL/6 mice fed a high-fat diet. 
 Working hypothesis:  Mango supplementation will significantly attenuate the 
overexpression of pro-inflammatory cytokines which is prevalent in high-fat diet-
induced obesity, with a subsequent increase in anti-inflammatory cytokines. This 
will indicate that mango supplementation mediates a balance between pro- and 







The review includes an overview of the growing trend of obesity and type-2 
diabetes, (T2D), composition of the gut microbiota, effect of diet on gut microbiota, the 
role of gut microbiota in nutrition and health, the role of gut microbiota in obesity and 
T2D, and the nutritional and health value of mango. 
 
The Growing Trend of Obesity and T2D  
Obesity is increasingly becoming a major public health problem globally. 
Available data suggest that obesity in adults is likely to keep accelerating in the near 
future due to increasing obesity in children and adolescents [28]. A study conducted 
among preschool children in urban areas of China indicated that the prevalence of obesity 
increased from 1.5% to 12.6% within a 7-year period [29]. 
 In Europe, obesity is prevalent among women and especially in Southern and 
Eastern European countries [30]. In Great Britain specifically, it has been reported that 
the prevalence of obesity among adults more than doubled between 1980 and 2002 [31]. 
Somewhat surprisingly, this increasing trend of obesity has also been noted in 
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low-income countries, where most of the humanitarian assistance is driven towards 
combating starvation [32]. The United States is not immune from this pandemic. The 
prevalence of obesity (BMI ≥ 30) has continued to increase and the prevalence of 
overweight (BMI: 25 – 29.9) has also continued to increase in children and adolescents 
[33, 34]. Using the data from the National Health and Nutrition Examination Survey 
(NHANES 2003-2004), Ogden and colleagues [34] reported that 17.1% of US children 
and adolescents were overweight and 32.2% of adults were obese. Furthermore, 31% of 
those aged 60 years or older were reported to be obese in the year 2003 – 2004. Also, 
there is significant evidence that the United States has one of the highest obesity 
prevalence rates among western countries in the world [35].  Therefore, there is evidence 
that obesity is a growing problem globally and especially in the United States where it 
has been shown to be prevalent among all the age groups of the population. 
 The direct and indirect implications of obesity for a society are detrimental. For 
example, obesity plays a key role in development of other clinical disorders such as T2D, 
dyslipidemia, hypertension and cardiovascular disorders, with a prominent one being 
T2D [36, 37]. Various studies have reported the association of obesity with T2D and the 
increasing prevalence of T2D among the global population and especially in the United 
States. Wild et al., [38] estimated the global prevalence of T2D to be 2.8% in the year 
2000 and are predicted to rise to 4.4% in 2030 among all age-groups [38]. Specifically, 
the total number of people with T2D is expected to rise from 171 million in 2000 to about 
366 million in 2030 [38]. Moreover, the prevalence of T2D is higher in men than in 
women and with the proportion of people aged >65 years are the most affected [38]. 
8 
 
Given the increasing prevalence of obesity, it is probable that these figures represent an 
underestimate of future T2D prevalence. 
In the United States, T2D occurrences have been reported to have increased 
significantly over the years. Data from the National Health and Nutrition Examination 
Survey (NHANES, 1999-2002) showed that T2D cases increased from 5.1% between 
1988-1994 to 6.5% from 1999- 2002 [39]. Moreover, a follow-up study on the data from 
NHANES reported that the prevalence of diagnosed T2D increased from 6.5% (1999-
2002) to 7.8 % from 2003 to 2006, with significant increase noted in women, non-
Hispanic whites and expectedly, in obese individuals [40].  
 The increasing prevalence of obesity and T2D comes with detrimental 
implications. Thus, there is an escalating demand for researchers and health professionals 
to find possible answers to curb the growing trend of these chronic and unhealthy states. 
 
The Gut Microbiota 
 The human body habituates a unique population of microorganisms called the 
microbiota [41]. The microorganisms found in the human digestive tract, called the gut 
microbiota, are the subject of intense research. Microbial population densities may reach 
their maximum values in the colon with 1011 bacteria per gram of stool [42, 43]. These 
microorganisms colonize the gut right after birth, forming a complex community of 
organisms over the years that act as a barrier against the colonization of the gut by non-
established or pathogenic species [43]. At the moment, a thorough description of all 
intestinal bacteria does not exist for two main reasons:  
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• Microscopic observations can only enumerate about 30% of the microorganisms 
via culture-based characterization [44-46]. 
• The gut bacterial species are highly diverse. Moreover, the use of molecular tools 
has indicated that the majority of the dominant bacterial species observed in the 
fecal microbiota of an individual is specific to that individual and is influenced by 
environment and diet [47-49]. 
Most of the dominant taxonomic groups of the gut microbiota have been known for a 
long time and may be determined through culture techniques while others have been 
demonstrated only recently via molecular approaches such as metagenomics and single 
gene approach based on ribosomal RNA [43]. Culturable genera of the dominant fecal 
microbiota of adults are: Bacteriodes, Eubacterium, Ruminococcus, Clostridium and 
Bifidobacterium [46, 50]. 
 The non-culturable microorganisms include members of the phylum Firmicutes 
which comprises the Eubacterium rectale – Clostridium coccoides, representing up to 
31% of total bacteria in the gut [51-53]. The phylum Firmicutes also comprises of the 
Clostridium leptum group with the species Faecalibacterium prausnitzii, Ruminococcus 
albus and  Ruminococcus flavefaciens which represent about 16-22% of the dominant 
microbial group [53, 54]. Bacteroidetes are often present and share dominance with the 
above groups [43]. The phylum Actinobacteria is less consistently detected as dominant, 
but represents a few percentages of total bacteria. The phylum Actinobacteria comprises 
of bifidobacteria (0.7-10%) and bacteria of the Collinsella-Atopobium group (0.3-3.7% 
on average) [43]. Enterobacteria are more seldom observed in the top two logs of 
population of fecal microbiota (0.4-1%), similar to lactobacilli and streptococci (2%) 
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[54]. Other species that are found occasionally are related to Clostridium ramosum, 
Eubacterium cylindroides, Phascolarctobacterium, Verrucomicrobium, Sporomusa, 
Selenomonas or Veillonella [43]. 
 The ability to isolate and grow microorganisms in vitro remains a key step in 
building our gut microbiota knowledge base, especially considering that phylogeny does 
not provide information on the in situ activity of microbes. Thus, phylogenetic 
reassessment of the intestinal microbiota has been essentially restricted to the dominant 
fraction and the available knowledge of the subdominant bacteria, i.e., below 108 per 
gram of stool, may be incomplete [43]. Our present knowledge indicates that the gut 
microbiota is constituted by seven phyla, namely Bacteroidetes, Firmicutes, Fusobacteria, 
Verrucomicrobia, Proteobacteria, Actinobacteria and Cyanobacteria [55]. Among these, 
the most abundant species are found in the Firmicutes and Bacteroidetes as they 
constitute about 90% of the human gut microbiota [55].  
 
Methods for Assessing the Gut Microbiota  
 Sampling for gut microbiota analysis is often based on mucosal or stool samples [55]. 
However, ideal samples for gut microflora studies in humans may be mucosal samples since 
studies have shown that the biodiversity of fecal microbiota markedly differs from mucosal 
samples which may be more reflective of human disease [56, 57] . Due to the practical challenges 
posed by mucosal sampling in humans, stool samples are however often used as a proxy for gut 
microbiota studies due to the ease in collection compared to biopsy samples [55]. 
 Though early techniques involved culture-based approaches, these could only provide 
limited information about the composition of the gut microbiota since most of these bacteria 
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species are obligate anaerobes and are thus difficult to culture [55, 58]. However, recent 
advancements with the development of microbial culture chips and gel microdroplets allow for 
the culture of previously uncultured microbes [55]. As further highlighted in Table 1, an 
advantage of the culture technique is its cost effectiveness although it is labor intensive [55]. 
 Recently, culture-independent techniques have been developed to study the microbial 
composition of a sample. These methods target the 16S ribosomal RNA gene for bacterial 
identification since the 16S rRNA gene is the most conserved site and provides the highest 
variability for phylogenetic identification of different bacteria than the 5S and 23S rRNA genes 
[59, 60]. Initial analysis involves extraction of genomic DNA from mechanically disrupted stool 
samples. The double-stranded DNA is separated by high temperature, which is followed by 
annealing of the conserved regions on the 16S rRNA genes and subsequently followed by the 
creation of a new strand of dsDNA by DNA polymerase. Multiple repetitions result in the 
amplification of the 16S rRNA gene [55].  The 16S rRNA amplicons generated via PCR can then 
be subjected to various culture-independent techniques including denaturing gradient gel 
electrophoresis (DGGE), temperature gradient gel electrophoresis (TGGE), fluorescence in situ 
hybridization (FISH), DNA microarray and sequencing techniques [55]. The description of these 
techniques, advantages and disadvantages are highlighted in Table 1. 
 The most recent technique developed to study the microbiome is known as metagenomic 
sequencing (also called metagenomics) [55]. Unlike the 16S rRNA gene profiling which only 
allows for understanding the composition of the gut microbiota and making comparisons between 
a healthy state and a diseased state, metagenomics allows for a more detailed understanding the 
biological and clinical significance, or the functional potential of the bacterial community present 
[55, 58]. This has the potential to take investigators into the next step of identifying which 
organisms are present and what they do. However, the computational analysis of data and 
bioinformatics that comes with it can be very daunting (Table 1) [55]. 
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Table 1:  Assessment techniques for gut microbiota characterization. ( Fraher et al., [55]) 
Technique Description Advantages Disadvantages 
Culture Bacteria isolation on selective media Cost-effective, semi-quantitative Labor intensive, limited culturable 
organisms 
qPCR Amplification and quantification of 16S 
rRNA. Reaction mixture contains a compound 
that fluoresces when it binds to dsDNA 
Plylogenetic identification, 
quantitative, fast 
PCR bias, unable to identify 
unknown species 
DGGE/TGGE Gel separation of 16S rRNA amplicons using 
denaturant/temperature 
Fast, semi-quantitative, bands can 
be excised for further analysis 
No phylogenetic identification, 
PCR bias 
T-RFLP Fluorescently labelled primers are amplified 
and then restriction enzymes are used to 
digest the 16S rRNA amplicon. Digested 
fragments separated by gel electrophoresis 
Fast, semi-quantitative, cheap No phylogenetic identification, 
PCR bias, low resolution 
FISH Fluorescently labelled oligonucleotide probes 
hybridize complementary target 16S rRNA 
sequences. Following hybridization, 
fluorescence can be enumerated using flow 
cytometry 
Phylogenenetic identification, 
semi-quantitative, no PCR bias 
Dependent on probe sequences, 
cannot identify unknown species 
DNA microarrays Fluorescently labelled oligonucleotide probes 
hybridize with complementary nucleotide 
sequences. Fluorescence detected with a laser. 
Phylogenetic identification, semi-
quantitative, fast 
Cross hybridization, PCR bias, 
species present in low levels can 
be difficult to detect 
Cloned 16S rRNA 
gene sequencing 
Cloning of full-length 16S rRNA amplicon, 




PCR bias, laborious, expensive, 
cloning bias 
Direct sequencing of 
16S rRNA amplicons 
Massive parallel sequencing of partial 16S 
rRNA amplicons 
Phylogenetic identification, 
quantitative, fast, identification of 
unknown bacteria 
PCR bias, expensive, laborious 
Microbiome shotgun 
sequencing  
Massive parallel sequencing of the whole 
genome (e.g 454 pyrosequencing, or Illumina) 
Phylogenetic identification, 
quantitative 
Expensive, intense computational 
data analysis 
Abbreviations:  qPCR: quantitative polymerase chain reaction, DGGE: denaturing gradient gel electrophoresis; TGGE: temperature gradient gel 
electrophoresis, T-RFLP: terminal restriction fragment length polymorphism, FISH: fluorescence in situ hybridization
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Effect of Diet on the Gut Microbiota 
 The impact of diet on the composition of the gut microbiota commences early in 
life. Colonization of the gut begins at birth and following an initial irregular community 
structure during the first year of life, the human gut microbiota becomes more stable and 
adult-like, coinciding with the introduction of solid foods into the diet [61, 62]. Pediatric 
studies have consistently shown that there is higher proportion of Bifidobacteria in 
breast-fed infants as compared to formula-fed infants [63, 64]. Human milk 
oligosaccharides are considered functional growth factors for the beneficial gut bacteria, 
as inhibitory receptors binding to different pathogens, and promote the development of 
the early immune system [65]. Generally, dietary components that impact the gut 
microbiota include non-digestible food components and polyphenols. 
 Non-digestible Food Components 
 Diet directly influences microbial composition and metabolic activity by making 
substrates available in the form of undigestible dietary residues that are resistant to 
digestive enzymes and the digestion process [66]. As the non-digestible food components 
reach the human colon, they interact with microbiota and epithelial cells, serving as food 
to the resident colonic bacteria and stimulating their fermentative capacity [66, 67]. All 
plant food constituents that are resistant to digestion and absorption in the human small 
intestine, with complete or partial fermentation in the large intestine are part of the 
indigestible fraction serving as dietary substrates to the microbiota [68]. This indigestible 
fraction comprises of non-digestible carbohydrates such as non-starch polysaccharides, 
resistant starch and oligosaccharides, and also other non-carbohydrate compounds such 
14 
 
as lignin, resistant protein, polyphenols and carotenoids which possess antioxidant 
properties [68].   
 The non-digestible carbohydrates are all together broken down to intermediate 
products such as lactate, succinate, pyruvate, and short chain fatty acids (SCFA) such as 
acetate, propionate and butyrate by the gut bacteria [69]. The SCFA may serve as food to 
the gut microbiota and they may also be absorbed for the body’s use. For example, 
butyrate has been described to promote the proliferation of beneficial bacteria species in 
the gut [67], while acetate and propionate has been revealed to impact liver and adipose 
metabolism [12, 13] . 
 The diet undoubtedly has an influence on the gut environment. Along with a 
reduction in gut transit time, increase in fiber intake has been reported to also increase 
total bacterial numbers and concentrations of bacterial fermented products [70]. 
Simultaneously, an increase in bacterial colonic fermentation results in a decrease in the 
pH in the proximal colon which results from high concentrations of short-chain fatty 
acids [71]. Previous studies have shown the importance of this colonic decrease in pH 
made possible by high fiber intake. Duncan and colleagues [72] reported that a one-unit 
decrease in pH (6.5 to 5.5) had a significant effect on selective species of the colonic 
microbial community, with a tendency to suppress Bacteroides spp. and promoting 
butyrate-producing gram-positive bacteria, such as Roseburia spp and Eubacterium 
rectale. 
Furthermore, a decreased total carbohydrate intake in weight loss diets is often 
expected to be accompanied by some reduction in dietary fiber and resistant starch. The 
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provision of such diets to obese subjects has been shown to result in decreased 
concentrations of microbially-produced SCFA in fecal samples, together with a 
significant decrease in the proportion and total numbers of Bifidobacteria and butyrate-
producing Lachnospiraceae related to Roseburia [73]. Therefore, it is expected that non-
digestible food fractions and diet-driven changes in pH and gut transit influenced by 
fiber, will be reflective on the composition of the gut and fecal microbiota. 
 Polyphenols 
Polyphenols are chemical compounds containing more than one hydroxyl group 
attached to a benzene ring [74]. These compounds are produced by plants and are 
generally classified as flavonoid and non-flavonoid compounds [74]. Polyphenols are 
considered beneficial to human health due to their free-radical scavenging ability, thus 
preventing membrane lipid oxidation [75]. Apart from the antioxidant ability of 
polyphenols, they may also be anti-inflammatory due to their ability to modulate the 
expression of NF-kB related genes involved in inflammation [74]. 
Unlike non-digestible carbohydrates, polyphenols do not lead to production of 
SCFA [76]. In foods and beverages, a substantial part of total phenolic compounds can be 
accounted for by the polyphenols bound to the food indigestible fraction [77]. While a 
small proportion of some dietary polyphenols can be absorbed through the small 
intestine, the majority are either not absorbed and become fermentable substrates for 
bacterial microflora in the colon along with the non-digestible food fraction [78]. The gut 
microbiota promotes the biotransformation of these polyphenols in the colon, making 
them available for colonic absorption [79]. 
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 Our understanding of the impact of polyphenols on the gut microbiota is evolving. 
It has been reported that dietary polyphenols may play a significant role in the 
modification of the gut microbial community [80, 81]. In vitro evidence has shown that 
flavonoids such as naringenin, diosmetin, ponciretin, and hesperetin inhibited the growth 
of pathogenic bacteria such as Helicobacter pylori [82] while catechin prevented the 
growth of Clostridium histolyticum [83]. Furthermore, a diet rich in tannins or 
polyphenols significantly slowed down the growth of Clostridium spp with a 
simultaneous stimulation of Bacteroides and Lactobacillus [84, 85]. Therefore, apart 
from their antioxidant and free-radical scavenging capacity, polyphenols may play a role 
in modifying the gut microbiota. 
 
The Role of Gut Microbiota in Nutrition and Health 
 As previously noted, the food non-digestible fraction serves as a substrate for the 
survival of the microbiota. In turn, the microbiota metabolizes the non-digestible fraction 
to produce a variety of products, including SCFA. Absorption of microbially-produced 
SCFA provides additional energy to the host from dietary components that have remained 
undigested in the small intestine [9]. Therefore, the gut microbiota contributes to the 
energy harvest from the diet, and this contribution might be essential under conditions of 
food scarcity [86].  
The caloric value per mole of non-digestible carbohydrate is considerably lower 
than that of a fully digestible carbohydrate and is also dependent on the extent of 
microbial fermentation and SCFA absorption [87]. For example, glucose and fructose 
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with a caloric value of 3.9 kcal/g produces approximately 38 mol ATP/mol while inulin 
and oligofructose has a caloric value ranging between 0 and 2.5 kcal/g, and may produce 
up to 17 mol ATP/mol [87]. This implies that directly replacing digestible carbohydrate 
by non-digestible carbohydrate in the diet should reduce the net delivery of calories to the 
host, assuming equal intake [9]. Evidence indicates also that the action of the intestinal 
microbiota on non-digestible carbohydrates might contribute to satiety [88]. 
 Furthermore, the gut microbiota is essential in the metabolism of polyphenols. 
They are capable of performing a range of biotransformations on polyphenols that pass 
into the colon, thus affecting polyphenol absorption and bioavailability [89]. The genera 
Clostridium and Eubacterium have been identified as involved in the metabolism of 
many phenolic compounds such as isoflavone (daidzein), flavonol (quercetin and 
kaempferol), flavonone (naringenin and isoxanthumol), and flavan-3-ol (catechin and 
epicatechin) which enhances their absorption [79].  In addition, colonic fermentation of 
polyphenols yield a broad spectrum of absorbable biotransformation products, which 
include valeric acid, valerolactone, phenylpropionic acid, phenylacetic acid, 
phenylbutyric acid, phloroglucinol, urolithin A and urolithin B [76]. The 
biotransformation and promotion of polyphenol absorption by the gut microbiota may 
thus be vital in assessing the wide health benefits of these plant chemicals. 
Some species of Bacteroides, Clostridium and Eubacterium are known to differ 
from the beneficial bacteria and thus considered detrimental because they possess 
enzymatic activities related to the generation of carcinogens [90]. In contrast, certain 
species belonging to the genera Lactobacillus and Bifidobacterium are considered 
18 
 
beneficial microorganisms and are commonly used as probiotics in the manufacture of 
functional food products [76]. 
 The gut microbiota is considered to play an important role in the prevention of 
sporadic colorectal cancer through the production of butyrate and the transformation of 
certain dietary polyphenols [91]. However, cancer-promoting compounds can also be 
produced by microbial activity, thus, the balance of procarcinogenic and anticarcinogenic 
microbial actions is vital and has been reported to be highly dependent on diet and 
xenobiotic intake [92]. A 2012 study conducted by Wang and colleagues [93] reported a 
change in gut bacteria, especially butyrate producers, in patients with colorectal cancer 
and healthy control groups. 
 Other health properties have been attributed to the beneficial bacteria in the gut. 
These include inhibition of a wide range of pathogens, improvement of lactose digestion, 
reduction of serum cholesterol, stimulation of anti-inflammatory cytokine production, 
reinforcement of intestinal epithelial cell tight junctions and increased mucus secretion 
[94-96]. 
 
Metabolism and Benefits of Short-Chain Fatty Acids 
 The production of SCFAs largely depends on the consumption of non-digestible 
carbohydrates from the diet such as resistant starch and fiber [97]. The main SCFAs 
resulting from colonic fermentation are acetate, propionate and butyrate [97]. The 
production of these SCFAs rely on the microbiota composition and environmental 
conditions such as substrate availability, pH and hydrogen partial pressure [97]. Acetate 
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is produced from H2 and CO2 by acetogenic bacteria such as Blautia hydrogenotrophica, 
a strict anaerobe belonging to the Firmicutes family [98]. Acetate may also be produced 
from formate through the Wood-Ljungdahl pathway by B. hydrogenotrophica [98]. 
 Propionate is majorly produced by Bacteroidetes and few Firmicutes such as 
Veillonella spp. and Dialister spp. through the succinate pathway [97]. Moreover, 
propionate may also be produced via the acrylate pathway, which uses lactate as a 
substrate or via the propanediol pathway by some Firmicutes and Proteobacteria, using 
deoxyhexose sugars like rhamnose as substrates [97].  
 Butyrate is largely produced by some Firmicutes using the enzyme, butyryl-
CoA:acetate CoA-transferase and to lesser extent, butyrate kinase and 
phosphotransbutyrylase [99]. The species belonging to the Firmicutes that utilizes acetate  
the butyryl-CoA:acetate CoA-transferase enzyme include Anaerostipes spp, Roseburia 
spp., E. hallii, F. prausnitzii, and E. rectale [97]. Furthermore, E. hallii and Anaerostipes 
spp are capable of producing butyrate from both acetate and lactate [100]. 
 The SCFAs have been established to possess a wide range of beneficial effects 
both within and outside the gut. Within the gut, butyrate is preferred as a source of energy 
by intestinal epithelial cells while propionate is majorly metabolized in the liver [97]. 
Also, microbial production of SCFAs may play a vital role in glucose homeostasis via 
incretin secretion. Strong evidence from animal models show that SCFAs may interact 
with their receptors, free fatty acid receptors 2 and 3 (FFAR2 and FFAR3) also known as 
GPR43 and GPR41 respectively, to induce the secretion of incretins from the 
enteroendocrine L and K cells of the intestine [14, 101]. Furthermore, intracellular 
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propionate and butyrate have been reported for their anti-inflammatory ability, capable of 
down-regulation of interleukin-6 (IL-6) and IL-12 in colonic macrophages [102-104]. 
Moreover, butyrate and propionate have been shown to induce the differentiation of T-
regulatory cells expressing the transcription factor, forkhead box P3 (FOXP3) [105, 106]. 
This process may be vital in the control of gut inflammation, since T-reg cells are 
important to tolerize the gut by tempering the pro-inflammatory status which may be 
created by the presence of commensal bacteria or pathogens [107] . 
 Extracellular SCFAs are also capable of vital interactions with a class of cell-
surface receptors known as G protein-coupled receptors [108]. While GPR109A 
recognizes only butyrate, GPR43 interacts with all three major SCFAs [109, 110]. The 
anti-inflammatory and gut-protective abilities of these SCFAs associated with high fiber 
intake have been proposed to be via their interactions with these receptors [97, 111]. For 
example, the interaction of butyrate with GPR109A has been reported to promote the 
differentiation of Treg cells and IL-10 producing T cells, inhibit the activation of nuclear 
factor kappa B (NF-KB) [110, 112]. This is also similar to the effect of acetate and 
propionate interaction with GPR43 [113].   These beneficial effects of the SCFAs are not 
only important for host cells but also contribute to the gut microbiota homeostasis [97]. 
 
The Gut Microbiota in Obesity 
 Obesity is considered a worldwide epidemic, a major health problem in both 
developed and developing countries. It has many complications, as it is a significant risk 
factor for other diseases such as T2D, cardiovascular diseases and cancer [114, 115]. 
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Apart from the widely known causes of obesity, it has recently been associated with a 
modification in microbiota, including a higher Firmicutes/Bacteroidetes ratio and a 
decrease in Methanobrevibacter smithii [86, 116]. 
 In addition, other studies have further associated imbalances in gut microbial 
population with obesity [117, 118]. Ridaura and colleagues [117] notably reported that 
transplanting the fecal microbiota of obese humans into germ-free mice increased fat-
mass and obesity-related metabolic phenotypes in these mice compared to when 
corresponding fecal microbiota from lean monozygotic twins was transplanted into 
another group of germ-free mice. Another study associated the mucin-degrading 
bacterium Akkermansia muciniphila with obesity and T2D [118]. The study showed that 
the abundance of A. muciniphila decreased in obese and T2D mice and that treatment 
with prebiotic normalized A. muciniphila levels, which in turn correlated with an 
improved metabolic profile [118].  
Furthermore, high-fat diets have been reported to result in a high degree of gut 
microbial dysbiosis which is often characterized by reduction in Bifidobacterium spp, 
Bacteroides-related bacteria, Lactobacillus spp and Roseburia spp, with Firmicutes 
generally becoming more abundant [22, 119, 120].  
Although alterations in the gut microbiome in obesity has been widely 
established, the mechanisms by which they might contribute to obesity is currently being 
investigated. A study from germ-free and conventionalized mice showed that 
conventionalization resulted in a significant increase in small intestine villi capillary 
density, leading to enhanced uptake of monosaccharide, with the promotion of hepatic 
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and adipose fat accumulation via sterol regulatory element binding protein-1 (SREBP-1) 
–regulated lipogenesis [121]. Furthermore, the gut microbiota promotes triglycerides 
storage in the adipocytes via the suppression of intestinal fasting-induced adipocyte 
factor (FIAF), which is known to inhibit adipose tissue lipoprotein lipase [121]. 
Moreover, the gut microbiota has been implicated in the promotion of liver steatosis, by 
reducing the bioavailability of dietary choline which is vital in VLDL synthesis and 
secretion in the liver [122]. In addition, the microbiome of mice fed a western diet (high 
fat, high sugar) was enriched in pathways involved in fermentation of simple sugars and 
glycans, coupled with a significant increase in phosphotransferase enzymes vital in the 
import of simple sugars [123]. These evidences strongly show that the gut microbiota 
may contribute to obesity via increase in dietary energy harvest, and distorted fatty acid 
metabolism. 
Interestingly, the gut microbiota has been proposed as a significant link between 
obesity and its associated comorbidities [124]. Obesity is associated with elevated levels 
of bacterial lipopolysaccharide (LPS), which is the major component of the outer 
membrane of gram-negative bacteria [125, 126]. The transit of LPS into the circulatory 
system, known as metabolic endotoxemia, reflects passage of bacterial fragments across 
the intestinal epithelial layer into the systemic circulation, partly due to increased 
intestinal permeability [127]. Endotoxemia is associated with the loss of gut 
Bifidobacterium spp., which is known to increase/maintain mucosal barrier function 
against pathogenic bacteria and bacterial antigens [128, 129]. Furthermore, increased 
intestinal permeability in obesity may be due to an impaired epithelial tight junction 
[130]. Feeding a high-fat diet in mice significantly reduced the expression of occludin 
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and tight junction protein 1 (ZO-1) which are epithelial tight junction proteins, resulting 
into increased entry of LPS into the blood [130]. LPS is capable of triggering an innate 
immune response by binding to the CD14/TLR-4 complex [131]. The result of this is an 
inflammatory state, characterized by elevated NF-kB mediated production of 
proinflammatory cytokines, especially TNF-α and IL-6, thereby promoting tissue insulin 
resistance [131, 132]. Moreover, it has also been reported that endotoxemia is a 
significant risk factor for development of early atherosclerosis, linking LPS and 
cardiovascular disease [133].  The results of these studies reveal that the gut microbiota 
might play a significant role in the pathogenesis of obesity and its detrimental outcomes. 
 
Nutrition and Health Value of Mango 
 Mango, also known as Mangifera indica, is a tropical fruit which varies in shape 
and size. It contains a thick yellow pulp, single seed and thick yellowish-red skin when 
ripe [24]. The seed is solitary, ovoid and enclosed in a hard, compressed fibrous endocarp 
[24]. 
Although there are variations in the nutritional composition of mango based on 
the variety, it is generally a rich source of fiber and polyphenols which, as discussed 
previously, are essential substrates in maintaining the balance of the gut microbiota, and 
thus, preventing immune dysregulation [23, 70, 77]. A study which investigated the total 
phenolic content and in vitro antioxidant capacity of five varieties of mango showed that 
Kent, Keitt, Haden and Tommy Atkins had similar total phenolic contents and 
antioxidant capacity [134]. However, this study observed that in comparison to other 
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varieties, the Ataulfo mango had significantly higher total phenolics and in vitro 
antioxidant capacity as measured by DPPH radical scavenging activities [134]. 
Furthermore, a recent study which reported the composition of two mango varieties noted 
that the total dietary fiber content of Ataulfo and Tommy Atkins mangoes were 225mg/g 
and 387mg/g (dry weight), respectively [23]. Furthermore, mango has a total fiber 
content comprising of about 50% soluble fiber [135, 136]. 
 The medicinal value of mango seems to be dependent on the parts of mango tree 
and its cultivar. Although mango is often obtained from the diet in the form of its pulp, 
other parts of the mango fruit (skin) and the tree (bark and leaves) have been 
predominantly studied [26]. Mango is regarded as a valuable dietary source of 
phytochemicals which provide health benefit for the nervous system [135]. Also, mango 
fruit is a good source of phenolic compounds such as mangiferin and flavonoids, which 
may contribute to its antioxidant and anti-inflammatory properties [137]. Other phenolic 
compounds which has been reported in mango fruit are gallic acid, chlorogenic acid, 
vanillic acid and protocatechuic acid, with increasing antioxidant contributions during 
ripening [138].  
Various evidences exist of the beneficial effects derived from different parts of 
mango. In vitro studies revealed that extracts from mango fruit peel inhibit adipogenesis 
in a 3T3-L1 pre-adipocyte cell line, with inhibition potency dependent on the variety of 
mango [139]. Similarly, treatment of 3T3-L1 adipocytes with mango seed kernel extract 
was reported to inhibit adipogenesis by down-regulating the adipogenic transcription 
factors peroxisome proliferator-activated receptor gamma (PPARγ) and 
CCAAT/enhancer binding protein alpha (C/EBPα) [140]. Also, evidence showed that 
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mango may possess chemopreventive property as reported in the study of Noratto et al 
[141] , which revealed that mango pulp extract of the Ataulfo variety inhibited growth of 
colon SW-100 cancer cells by 72% and induced the expression of pro-apoptotic 
biomarkers. 
Furthermore, various studies using animal models have established the potential 
health benefits of mango. Sharma and others [142] studied the hypoglycemic potential of 
mango leaves in diabetic rats and reported a significant hypoglycemic effect of the leaf 
extract at a dose of 250 mg/kg suggesting an anti-diabetic effect of mango leaves. In 
addition, ethanolic extract of mango fruit has been reported to improve age-related and 
scopolamine-induced cognitive deficit in mice [143]. Using a high-fat animal model, 
Lucas and colleagues [26] reported that freeze-dried mango pulp modulates blood 
glucose in a similar pattern to the popular glucose-lowering medication, rosiglitazone 
(Avandia), used in the treatment of T2D and which has been associated with increased 
bone fractures and rapid bone loss. Interestingly in this study, it was reported that mango 
preserved bone parameters and thus, skeletal health was not affected in contrast to 
rosiglitazone [26].  In addition, 1% and 10% mango pulp supplementation in high fat 
diet-fed mice resulted in a significant reduction in percent body fat to levels similar to 
control animals while the 1% dose lowered blood glucose levels independent of body 
weight gain [25].  
Few studies have investigated the benefits of mango supplementation in humans 
[144, 145].  A 12-week freeze-dried mango supplementation in obese adults resulted in 
the reduction of fasting blood glucose in these subjects [144]. Furthermore, 
normolipidemic volunteers who consumed whole mango or fresh cut mango for 30 days 
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had a reduction in fasting plasma triglyceride levels with an increase in plasma 
antioxidant capacity [145]. These studies suggest that mango may be an affordable 
alternative in managing high fat diet-induced fat accumulation and T2D. Other reported 
health benefits of mango has been reviewed in detail by Shah et al. (12). Due to the 
reported health benefits of mango, the purpose of this study is to determine the effects of 
freeze-dried mango pulp on the gut microbiota and its impact on body composition, blood 






Animals and Treatment Groups   
 Sixty 6-week old male C57BL/6 mice were purchased from Charles River 
Laboratory (Portage, MI). Following a 1-week acclimatization period, mice were 
randomly assigned to one of four treatment groups (Table 2) for 90 days. Mice were 
housed in groups of 3-4 mice per cage. To minimize corophagic activity, wire bottom 
cages were used for housing. 
Table 2: Treatment groups 
Group     Dietary Treatment  
(n= 15 mice/group) 
1             Control diet (10% kcal from fat)                   
2             High fat diet (HF; 60% kcal from fat)                 
3             HF+1% freeze-dried mango diet (w/w)            
4             HF+10% freeze-dried mango (w/w)          
 
For the mango diet, the variety and doses were based on our earlier study [25]. 
Ripe mango of the Tommy Atkins variety were purchased from a local grocery store and 
peeled. The pulp were freeze-dried, ground, and added at a dose of 1 and 10 % (w/w).
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Mango composition was determined at NP Analytical laboratory (St. Louis, MO) (Table 
3). All diets were prepared at Harlan-Teklad Laboratories (Madison, WI) and have the 
same macronutrient, calcium, and phosphorus content (Table 4). 
Table 3: Mango composition 










Mice were given access to food and deionized water ad libitum. Food intake was 
monitored thrice a week and body weights recorded on a weekly basis. All procedures 
strictly adhered to the guidelines set forth by the Oklahoma State University Animal Care 







Table 4: Diet composition (g/kg)1 
Ingredients Control High Fat 
(60% Fat) 
HF + 1% Mango HF + 10% Mango 
g / kg diet 
Mango - - 10 100 
Casein 140.00 180.00 179.46 174.56 
L-Cystine 1.80 1.80 1.8 1.80 
Corn Starch 465.692 116.00 107.1145 27.327 
Maltodextrin 155.00 155.00 155.0 155.00 
Sucrose 100.00 106.826 106.826 106.826 
Lard - 310.00 310.0 310.00 
Soybean Oil 40.00 40.00 39.871 38.569 
Cellulose 50.00 50.00 49.5775 45.775 
Mineral Mix2 
 
35.00 13.4 13.4 13.40 
Calcium Carbonate - 6.979 6.978 6.97 
Calcium Phosphate, 
dibasic 
- 7.487 7.465 7.265 
Vitamin Mix 
(TD 94047) 3 
10.00 10.00 10.0 10.0 





0.008 0.008 0.008 0.008 
1Prepared at Harlan-Teklad Laboratories (Madison, WI) 
2Complete mineral mix (TD94049, Harlan-Teklad Laboratories) was used for the control 
diet and a calcium and phosphorus deficient mineral mix (TD 98057, Harlan-Teklad 
Laboratories) was used for the mango and HF diets. 
3 Harlan-Teklad Laboratories (Madison, WI) 
 
Necropsy and Tissue Processing 
At the end of the 90 days treatment, mice were fasted for three hours starting at 5 
am, with mice having access only to water. After fasting, the body composition of each 
mouse was assessed using a whole body PixiMus scan (GE Lunar, Madison, WI). 
Afterwards, mice were bled from their carotid artery and blood was collected in 
microcentrifuge tubes (Axygen Inc, Union City, CA) coated with EDTA (Amresco, 
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Solon, OH) as an anticoagulant. Plasma samples were obtained by centrifugation of 
whole blood samples at 4oC for 10 minutes at 1500 x g . An aliquot of each plasma 
sample was transferred into microcentrifuge tubes and stored at -80oC until analyses.  
The liver, white adipose tissue, pancreas, spleen, and thymus were snap-frozen for 
later analyses. The ileum and jejenum were flushed with ice-cold saline (0.9% NaCl) and 
Peyer’s patches were removed from the ileum. The Peyer’s patches and ileum were then 
snap-frozen and stored at -80oC for future analyses. Furthermore, the colon was flushed 
with ice-cold saline, and an incision was made to open it up. The colon was placed on a 
glass board with the lamina propria (LP) facing up. The colon lamina propria was 
removed by gently scraping with the edge of a glass slide. The colon LP samples were 
collected in microcentrifuge tubes and stored at -800C for gene expression analyses. In 
addition, the cecum was harvested and its contents were flushed into pre-weighed and 
pre-cooled 15 mL centrifuge tubes (VWR Intl. LLC Randor, PA) with ice-cold saline, 
after which the cecal tissue was weighed and snap-frozen. Flushed cecal contents were 
centrifuged, (4oC, 5 minutes, 1800 x g) and the supernatant discarded. Samples were kept 
frozen at -80oC until analyses of cecal microbiota. 
 
Measurements and Assays 
Gut Microbiota 
For the determination of possible changes in the gut microbiota affected by 
mango supplementation, frozen cecal samples were shipped overnight on dry ice to 
Second Genome Inc (San Francisco, CA). From the cecal samples, Second Genome 
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performed DNA isolation with the MoBio PowerMag Microbiome kit (Carlsbad, CA) 
followed by concentration normalization. To ensure all samples met minimum 
concentration and DNA mass, samples were quantified using the Qubit Quant-iT dsDNA 
Broad-Range Kit (Invitrogen, Life Technologies, Grand Island, NY). This was followed 
by DNA amplification so as to enrich the samples for bacterial 16S V4 rDNA region. 
This was done using fusion primers designed against surrounding conserved regions 
which are tailed with sequences incorporating Illumina adapters and indexing barcodes 
(San Diego, CA). Samples were PCR amplified with two differently barcoded V4 fusion 
primers, and their amplification products quantified by qPCR. Samples that met post-
PCR quantification minimum were used for pooling and sequencing. A pool containing 
16S V4 enriched, amplified and barcoded samples were loaded into the cartridge on a 
MiSeq instrument (Illumina, San Diego, CA) for cluster formation. This was followed by 
sequencing for 2x250 cycles using custom primers designed for pair-end sequencing.  
In order to determine the Operational Taxonomic Unit (OTU) present in the 
samples, sequenced pair-end reads were merged and dereplicated with USEARCH as 
described by Edgar [146]. Unique sequences were then clustered at 97% similarity by 
UPARSE and a representative consensus sequenced per de novo OTU was determined. 
Representative OTU sequences were then assigned taxonomic classification via Mothur’s 
Bayesian classifier trained against the Greengenes reference database of 16S rRNA gene 
sequences with 80% classification confidence. 
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Glucose Tolerance Test (GTT) 
 GTT was performed on the 87th day of dietary treatment. Mice were fasted for 6 
hours prior to GTT. Each mouse was injected intraperitoneally with a 20% glucose 
solution at a dose of 2 g/kg body weight. Blood glucose was measured from tail blood 
samples at 0, 5, 15, 30, 60, and 120 minutes post glucose challenge, using an AlphaTrak 
glucometer (Abbott Laboratories, Illinois, USA). 
Determination of Plasma Lipids 
Frozen plasma samples were allowed to thaw on ice and the concentrations of 
total cholesterol, triglycerides, high density lipoproteins (HDL), and non-esterified fatty 
acids (NEFA) was determined using the automated analyzer, BioLis 24i (Carolina 
Chemistry, Winston-Salem, NC) following manufacturer’s instructions.  For cholesterol 
determination, cholesterol esters are hydrolyzed to free cholesterol and fatty acids by 
cholesterol esterase. The free cholesterol generated is subsequently oxidized by 
cholesterol oxidase to cholesterol-4-en-3-one and hydrogen peroxide which upon the 
action of peroxidase, forms a quinone dye which can be read at 505 nm giving a 
proportional value to the total cholesterol present in the sample. The principle of 
triglyceride determination involves lipase hydrolysis of triglycerides in the sample to 
glycerol and free fatty acids. This is followed by 3 coupled enzymatic steps which uses 
glycerol kinase, glycerophosphate oxidase and peroxidase, resulting in the formation of a 
colored complex which forms a red quinoneimine which can be read at 520 nm with the 
value directly proportional to the triglyceride concentration in the sample. HDL 
determination involves an initial disruption of the HDL lipoprotein to release cholesterol 
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followed by enzymatic reactions used for total cholesterol. NEFA measurement follows 
the principle of formation of acyl-CoA when NEFA is exposed to acyl-CoA synthetase in 
the presence of ATP and CoA. Acyl-Coa is oxidized by acyl-CoA oxidase to produce 
hydrogen peroxide which allows for the condensation of 3-methyl-N-ethyl-N-(b-
hydroxyethyl)-aniline with 4-aminoantipyrine in the presence of an added peroxidase to 
form a purple-colored product that can be measured at 550 nm, correlating to the amount 
of NEFA present in the sample. 
Determination of Plasma Incretins, Cytokines and Adipokines 
 Concentrations of plasma cytokines and adipokines were determined using the 
Bio-Plex suspension array system (Bio-Rad Laboratories Inc, Hercules, CA) according to 
manufacturer’s instructions. This system uses fluorescently dyed nanobeads with unique 
individual spectral address to allow multiple detection of different molecules in a single 
well of a 96-well plate [147]. For the determination of plasma cytokines, a mouse 23-Plex 
assay (Bio-Rad Cat No: #M60-009RDPD), consisting of fifteen cytokines (IL-1α, IL-1β, 
IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-17A, interferon 
gamma [IFN-γ], TNF-α), six chemokines (eotaxin, monocyte chemoattractant protein 
[MCP-1], macrophage inflammatory protein alpha [MIP1α], MIP-1β, regulated on 
activation, normal T expressed and secreted [RANTES], keratinocyte chemoattranctant 
[KC]) and two growth factors (granulocyte colony stimulating factor [G-CSF], 
granulocyte macrophage colony stimulating factor [GM-CSF]) was used. Moreover, for 
the determination of plasma adipokines, a mouse 8-plex assay kit (#171-F7001M), 
consisting of ghrelin, gastric inhibitory peptide (GIP), glucagon-like peptide 1 (GLP-1), 
34 
 
glucagon, insulin, leptin, plasminogen activator inhibitor 1 (PAI-1) and resistin was used. 
Both assays were run according to instructions included with the Bio-Rad kits.  
Briefly, plasma samples were reconstituted in sample diluent (1:4 v/v). Thereafter 
in a 96-well plate, 50 µL of diluted samples and standards (in duplicates) were mixed 
with 50 µL diluted 1x capture antibody-coated magnetic beads, covered with aluminum 
foil, and  shaken with an orbital shaker at 850 rpm at room temperature for 30 minutes. 
After three washes with 100 µL of wash buffer, 25 µL of detection antibodies was added, 
the plate was covered with aluminum foil, and shaken again at 850 rpm for 30 minutes. 
Following three washes with 100 µL of wash buffer, 50 µL of streptavidin-phycoerythrin 
(SA-PE) was added to detect each captured analyte, covered with aluminum foil and 
shaken at 850 rpm for 10 minutes. Beads were resuspended in 125 µL of assay buffer and 
analytes were thereafter quantified using a Bio-Plex MAGPIX Multiplex Reader (Bio-
Rad Laboratories Inc, Hercules, CA). Concentrations of analytes were determined using 
the Bio-Plex Manager (6.1) software.  
SCFA analysis 
The gut microbiota metabolize non-digestible food fraction into a variety of 
product, most notably short chain fatty acids [69, 78]. Thus, cecal and fecal SCFA 
content from mouse samples was determined according to a previously published method 
with modifications [148]. Three to four cecal samples were pooled in order to obtain a 
representative sample. Pooled cecal or fecal samples (1 g) were suspended in 900 µL or 
4.5 mL of ice-cold Millipore H2O (for cecal and fecal samples, respectively). An internal 
standard (10 mM of 2-ethylbutyric acid in 12% formic acid) was spiked into the sample 
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suspension resulting in a final concentration of 1 mM internal standard, and homogenized 
for 1 minutes or 3 minutes (for cecal and fecal samples, respectively). The pH of the 
resulting cecal and fecal homogenates was adjusted to 2 -3 using 5 M HCl. Samples were 
incubated at room temperature for 10 min followed by centrifugation (2200 x g, 20 min, 
15ºC). The resulting supernatants were filtered using 0.45 µm PTFE syringe filters 
(VWR, Cat No: 28145497) into a GC glass vials (Agilent Technologies, Santa Clara, 
CA). Gas chromatographic analyses were done at Robert M. Kerr Food and Agricultural 
Products Center (Oklahoma State University, Stillwater, OK) . 
GC analysis was carried out using an Agilent 6890N GC system with a flame 
ionizable detector (FID) and an N10149 automatic liquid sampler (Agilent Technologies, 
Santa Clara, CA). The column used was a fused-silica capillary column with a free fatty 
acid phase (DB-FFAP, Product #: 125-3237, Agilent Technologies, Santa Clara, CA), 
with hydrogen supplied as the carrier gas at a flow rate of 14.4 mL/min. The initial oven 
temperature was held for 0.5 minutes at 100ºC. This was raised to 180ºC for 1 minute at a 
rate of 8ºC/min, then to 225ºC for 10 minutes at 45ºC/min. Sample (1 µL) was injected 
into a splitless injection port with an initial temperature of 200ºC while the temperature of 
the FID was 240ºC. Calibration was done using standard solutions containing 400 mM of 
acetic acid, propionic acid and butyric acid, 200 mM for valeric and isovaleric acid, 100 
mM for isobutyric acid, 50 mM for caproic acid and 15 mM for heptanoic acid which 
were all purchased from Sigma-Aldrich (Milwaukee, WI).   
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Gene Expression Analysis by Quantitative Polymerase Chain Reaction (qPCR) 
SCFAs (propionate, acetate and butyrate) bind to G-protein coupled receptors to 
enhance secretion of gut hormones [108].  Prominent among these receptors is GRP43 
which is equally sensitive to each SCFA and is expressed in the ileum and colon [108]. 
GPR43 has been reported to mediate gut inflammation and stimulate incretin secretion 
[14, 111]. Therefore, relative gene expression of GPR43, the pro-inflammatory cytokines 
IL-1β and IL-6, and the anti-inflammatory cytokine IL-10, in each treatment group was 
determined from the colon mucosa and the ileum using qPCR. This assay was carried out 
following a previously described protocol [25]. Total RNA was extracted from the frozen 
colon mucosa and ileum using TRIzol reagent (Sigma-Aldrich). The concentration of the 
extracted RNA was verified using a Nanodrop spectrophotometer (Thermo Scientific, 
Wilmington, DE) and agarose gel electrophoresis was used to verify the quality of the 
18S and 28S rRNA. To generate cDNA, total RNA (2 µg) was treated with DNase I 
(Roche, IN) and reverse-transcribed using the SuperScript II synthesis system 
(Invitrogen, Grand Island, NY). Real-time quantitative PCR analysis was performed 
using SYBR Green chemistry on an ABI 7900HT sequence-detection system instrument 
and 2.4 SDS software (Applied Biosystems, CA). The complete list of the 
oligonucleotide primers used can be found in Table 5. The relative mRNA transcript 
levels were calculated according to the 2–ddCt method [149]. The results were presented 
relative to the control group.  
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Table 5:  Primer sequences for gene expression analysis  
Gene Forward Primer Reverse Primer 
mCyclo 5`-tgg aga gca cca aga cag aca-3` 5`-tgc cgg agt cga caa tga t-3` 
mFfar2 5`-ctt ccc ggt gca gta caa gt-3` 5`-gct ctt ggg tga agt tct cg-3` 
mIL-10 5`-ggt tgc caa gcc tta tcg ga-3` 5`-acc tgc tcc act gcc ttg ct-3` 
mIL-1b 5`-caa cca aca agt gat att ctc cat g-3` 5`-gat cca cac tct cca gct gca-3` 
mIL-6 5`-gag gat acc act ccc aac aga cc-3` 5`-aag tgc atc atc gtt gtt cat aca-3` 
 
Western Blot Analysis 
The interaction of short-chain fatty acids with GPR43 stimulates the release of 
incretins from the enteroendocrine L-cells of the small intestines [14]. Glucagon-like 
peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are anti-
hyperglycemic incretins, which increase insulin secretion, increase glucose sensitivity 
and enhance proliferation of β-cells [150]. To determine the possible effect of these 
incretins on pancreatic metabolism, relative protein expression of the incretin receptors, 
GLP-1R and GIPR was determined from the pancreas using western blot following the 
approach of Huang et al [151].  
To extract total protein, 50 mg of pancreas samples were lysed in 300 µl of RIPA 
buffer containing phosphate and protease inhibitor (Sigma Aldrich, St. Louis MO). The 
lysate was sonicated three times, (Misonix Inc, Farmingdale, NY) centrifuged at 8000 x 
g, for 10 mins at 4oC, and the total protein concentration was determined using Pierce 
BCA Protein Assay Kit (Pierce Biotechnology Inc, Rockford, IL). Protein samples (20 
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µg) were separated by SDS-PAGE using 10 % acrylamide-bis gels (acrylamide:bis, 
29:1). Thereafter, the samples were transferred to polyvinylidene fluoride (PVDF) 
membranes (ThermoScientific, Rockford, IL, Product # 88518). This was followed by 
incubation of the PVDF membranes with 5% powdered milk (Nestle, Colon, OH) at 
room temperature for 1 hour with gentle shaking. The membranes were thereafter probed 
with the following rabbit polyclonal antibodies: GLP-1R (1:200 dilution, Santa Cruz 
Biotech, Dallas, TX, Cat # sc-66911), GIPR (1:200 dilution, Santa Cruz Biotech, Dallas, 
TX, Cat # sc-98795) and β-Actin (1:1000 dilution, Cell Signaling Technology, Danvas, 
MA, Cat # 4967). The PVDF membranes were incubated with the antibodies overnight at 
4ºC with gentle shaking. The following day, the PVDF membranes were washed twice in 
PBS for 5 minutes and incubated with 5% powdered milk (Nestle, Solon, OH) at room 
temperature for 11/2 hours in order to block non-specific sites on the membrane. 
Thereafter, an anti-rabbit IgG, HRP-linked antibody (1:1000 dilution, Cell Signaling 
Technology, Danvas, MA) was incubated with the membrane for 1 hour on an orbital 
shaker. The membrane was then washed in PBS for 11/2 hours with the PBS changed 
every 15 minutes. Immunodetection of expression bands was carried out with Ponceau S 
Stain (Sigma-Aldrich, St Louis, MO) and viewed with FluorChem R Imaging System 
(ProteinSimple, San Jose, CA). The resulting bands were thereafter quantified using 
UNScanIT software, version (Silk Scientific Inc, Orem, UT). 
Liver Lipids Determination 
Total lipids, triglycerides and cholesterol were determined following a protocol 
described by Carr et al.,[152] with few modifications. Approximately 100 mg of mashed 
frozen liver samples was weighed on a filter paper, folded and sealed with a paper clip, 
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transferred to a 50 mL centrifuge tube, and extracted with a 2:1 (v/v) mixture of 
chloroform: methanol at room temperature for 3 days to allow for efficient lipid 
extraction. After the third day, 3.5 mL of 0.05% sulfuric acid was added to each tube, 
vortexed and allowed to stand for few minutes. The top layer was aspirated off and the 
remaining volume was estimated.  A duplicate aliquot (500 uL) was transferred into new 
test tubes for the triglyceride and total cholesterol determination. The triglyceride and 
total cholesterol content of the liver was determined from the previously taken aliquots 
using the BioLis 24i chemical analyzer (Carolina Chemistry, Wiston-Salem, NC) 
following manufacturer’s instructions. 
For determination of total lipids, aluminum weighing pans were oven-dried 
(1000C for 1 hour) and cooled in the desiccator for 30 minutes.  The remaining 
chloroform: methanol solution in the 50 mL centrifuge tubes was poured into the pre-
weighed aluminum pans and the solvent was evaporated off under the fume hood. 
Thereafter, the aluminum pans were again oven-dried (1000C for 1 hour) and cooled in 
the desiccator for 30 minutes. The weights of the aluminum pans were taken and the total 
liver lipid was calculated.  
 
Statistical Analyses 
For the gut microbiota data, univariate differential abundance of OTUs and the 
genus level was tested using a negative binomial Generalized Linear Model (GLM) for 
the overdispersion and Poisson process intrinsic to the data, which was implemented in 
the DESeq2 package [153]  and described for microbiome applications by McMurdie and 
Holmes [154]. DESeq2 was run under default settings and p-values were corrected for 
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false discovery rates with the Benjamini-Hochberg procedure [155]. Only OTUs with the 
adjusted p-value below 0.05 and more than one log2 fold change were reported. 
Apart from the gut microbial data, statistical analyses for other data involved 
computation of least square means and standard deviation of the means for each of the 
treatment groups using SAS version 9.1 (SAS Institute, Cary, NC). Data was checked for 
normal distribution using residual plots. Analysis of variance and least square means was 
calculated using the general linear model procedure and the means were compared using 
Fisher’s least significant difference for comparing groups. P value < 0.05 was considered 







 This study investigated the effects of mango supplementation in modulating the 
gut microbiota, and body composition, glucose and lipid metabolism in C57BL/6 mice 
fed a high fat diet. Furthermore, mango’s effect on microbial short chain fatty acid 
production, and modulation of gut inflammation was determined. 
 
Effects of Mango Supplementation on the Gut Microbiota in High Fat Diet-fed Mice 
We investigated the effect of 90-day mango supplementation in preventing the 
loss of beneficial gut bacteria due to high fat feeding. First, inter-sample relationships 
using a phylogenetic tree showed that phylum Firmicutes are the most abundant in the 
samples while the archaea phylum - Euryarchaeota was the least abundant (Figure 2a). 
Looking at genus-level changes in the cecal gut bacteria due to dietary feeding, the high 
fat diet resulted in a significant loss of the genera Akkermansia, Bifidobacterium, 
Sutterella, Ruminococcus, Collinsella, Coprobacillus, Staphylococcus and Oscillospora 
in comparison to the control group (Figure 2b). The bacterial genera that were 
significantly elevated in the high fat diet group are at the moment unclassified at the 
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genus level but majority belonged to the phylum Firmicutes (Figure 2b). The genus 
Dorea, Sutterella and  Ruminococcus were more abundant in the control group compared 
to the 1% mango diet group (Figure 2c) while the genus Lactococcus was more abundant 
in the 1% mango group compared to control. Similar results were observed with the 10% 
mango group as there was a significant increase in abundance of the lactic acid producing 
genera, Lactococcus and Lactobacillus in the 10% mango groups relative to the control 
(Figure 2d). In comparison to the high fat diet-fed group, the 1% mango group did not 
modulate any significant changes in any of the presently classified bacteria genera 
(Figure 2e). However, the greatest bacterial modulation was seen with the 10% mango 
group, as the genus Prevotella, Akkermansia, Bifidobacterium, Aldercreutzia, 
Ruminococcus were more abundant compared to the high fat diet-fed group, indicating a 
dose-dependent modulation of the gut bacteria by mango supplementation (Figure 2f).  
Impact of mango supplementation on body and tissue weights, food intake, body 
composition, glucose homeostasis and lipid metabolism 
Body weights were similar prior to initiation of the dietary treatments (Table 6). 
However, after 90 days of treatment, there were significant differences in body weight 
with the 10% mango supplemented group having the highest body weight. The mango 
supplemented groups also had a significantly higher caloric intake levels compared to the 
other groups (Table 6). Similarly, the HF+10% mango group have a significantly higher 
liver weight compared to the control while the high fat and HF+1% mango groups had an 
intermediate effect. Cecal tissue weight was highest in the 10% mango supplemented 
group. Spleen, pancreas and thymus weights were unaffected by mango supplementation. 
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In addition to isolating and weighing the abdominal fat, whole body composition 
was also assessed by a densitometer (PixiMus) at the end of dietary treatment.  Our 
results showed that mango supplementation had no effect in preventing abdominal fat 
accumulation due to high fat diet intake (Table 6). Mice fed the 10% mango have the 
highest abdominal fat weight, total fat mass, and % body fat. Additionally, lean mass was 
also high for this group.  
To determine the effects of mango supplementation on glucose homeostasis, 
glucose tolerance test was conducted. Furthermore, incretin (GLP-1 and GIP) and insulin 
levels were assessed in the plasma. Subsequently, since incretins are known to impact 
pancreatic metabolism and insulin release via the enteroinsular axis [156], protein 
expression of the incretin receptors (GLP-1R and GIPR) was assessed in the pancreas.  
In a similar pattern to the results on body composition, mango supplementation at both 
1% and 10% doses were unable to modulate glucose homeostasis as shown by the area 
under the curve values obtained after the glucose tolerance test, which were not 
statistically different from the HF group (Table 7). However, there was a dose-dependent 
increase in plasma insulin levels with statistical significance only seen with the 10% 
mango (Table 7). Incretin assessment in the plasma showed that the control group had a 
significantly lower GLP-1 level compared to other groups (Table 7). However, the 10% 
mango supplementation induced the greatest GLP-1 secretion (Table 7). GIP levels in the 
plasma remained unaffected by dietary supplementation (Table 7). In the pancreas, both 
mango doses had no significant effect on the expression of GLP-1R protein (Figure 3a). 
However, mango supplementation significantly increased the expression of GIPR in the 
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pancreas compared to the high fat group with the 1% mango dose having the greatest 
impact (Figure 3b). 
The effects of dietary treatment on lipid metabolism were assessed by measuring 
plasma and liver lipids as well as plasma adipokines (Table 8). Mango supplementation 
had a mixed effect on plasma lipid levels. Mango supplementation was not able to reduce 
plasma cholesterol levels due to high-fat feeding. Surprisingly, the 10% mango group 
showed significantly higher plasma cholesterol levels compared to other groups.  HDL 
levels was significantly higher in HF, HF+1% and HF+10% mango groups compared to 
the control, with non-HDL levels showing a similar pattern to the total cholesterol levels. 
Interestingly, triglyceride levels were significantly lower in both mango doses with the 
10% mango dose showing the highest reduction similar to the control. Furthermore, the 
10% mango dose modulated a significant reduction in plasma non-esterified fatty acids 
(NEFA) levels compared to all other groups. The modulation of plasma lipids by the 10% 
mango supplemented group could not be explained by changes in liver lipid metabolism 
as the HF and mango supplemented groups had significantly higher total lipid and 
triglyceride levels compared to the control. Finally, both mango doses showed a tendency 
to reduce the pro-inflammatory plasma adipokines (leptin and resistin), however, this did 
not reach statistical significance. 
Impact of mango supplementation on short chain fatty acid production and GPR43 
expression in mice fed a high-fat diet. 
Following 90 days of treatment, microbial SCFA production due to dietary 
treatment was assessed in the cecal and fecal contents via gas chromatography. In 
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addition, mRNA expression of an SCFA receptor, GPR43 was assessed in the ileum and 
colon mucosa. 
 SCFA analysis (Table 9) showed the impact of mango supplementation in 
modulating SCFA production as measured in cecal and fecal samples. High fat feeding 
resulted in a decrease of all SCFA measured in cecal samples while mango 
supplementation mediated an increase in SCFA production with the higher dose (10% 
mango) being the most effective at raising SCFA levels. Specifically, 1% mango 
supplementation significantly increased the levels of n-butyric acid and n-valeric acid 
compared to the high fat group in the fecal samples. The 10% mango-supplemented 
group however, had a significant increase in all the measured fecal SCFA (except 
propionate) in comparison to the high fat group. Similar results were seen with the cecal 
SCFA content as 10% mango supplementation led to a significant increase in all the 
SCFA measured compared to the high fat group, with the exception of propionic acid and 
valeric acid.  However, mango supplementation had no significant impact on the 
expression of the SCFA receptor, GPR43 in the ileum and colon (Figure 4a and 4b).  
Impact of mango supplementation on gut and plasma inflammatory markers in 
mice fed a high-fat diet. 
 In order to determine the possible immunomodulatory effect of mango 
supplementation in mice fed a high fat diet, we assessed the gene expression of 
proinflammatory markers (IL-6 and IL-1β) and an anti-inflammatory marker (IL-10) in 
the ileum and colon lamina propria. Furthermore, we assessed levels of various 
inflammatory markers in the plasma using the Bioplex Multiplex assay.  
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 In this study, dietary treatment had no effect on the gene expression of IL-1b in 
the ileum (Figure 5A). The high fat diet caused an increase in IL-6 expression in the 
ileum compared to the control (Figure 5A). Interestingly, mango supplementation 
significantly decreased IL-6 expression in the ileum in a dose-dependent manner (Figure 
5A). Mice fed the 1% mango diet had the highest expression of the anti-inflammatory 
marker, IL-10 in the ileum (Figure 5a). Similarly, results from the colon showed that both 
mango doses significantly increased the expression of IL-10 (Figure 5b). The reduction 
noticed in the expression of IL-1b and IL-6 in the colon with mango supplementation did 
not reach statistical significance. In the plasma, the immunomodulatory effect of mango 
supplementation noticed in the ileum and colon was not evident as dietary 
supplementation with mango had no significant impact on plasma cytokine levels except 






Figure 1:  Effects of dietary mango supplementation on cecal gut microbial 
population 
 





(b)   Feature selection - control (C) vs high fat (F) diet 
 
 





(d) Feature selection - control (C) vs high fat+10% mango (10P) diet 
 
 




(f) Feature selection - high fat (F) vs high fat+10% mango (10P) diet 
 
DNA isolated from cecal samples were subjected to 16S rDNA sequencing.  n = 4 
mice/group.  C=Control, F=High Fat, 1P=High fat+1% Mango, 10P = High fat+ 10% 
Mango.  (a) Phylogenetic tree at the Family level. The height of each bar indicates the 
number of samples containing that particular family.  (b-f) Genus level changes due to 
dietary treatment as presented by log 2 fold changes versus genus. Bars represent median 
value of each Genus and points are OTUs belonging to that Genus. (b,c,d)  Significantly 
elevated genera in C are on the positive axis (right) while elevated genera in F, 1P and 
10P are on the negative axis (left).  (e, f) Significantly elevated genera in F are on the 
positive axis (right) while elevated genera in 1P and 10P are on the negative axis (left).  
Features were considered significant if their FDR-corrected P-value ≤ 0.05, and the 
absolute value of their Log-2 Fold Change was greater than or equal to 1.  OTU = 
Operational Taxonomic Unit,  FDR = False Discovery Rate 
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Table 6:  Effects of freeze-dried mango supplementation on food intake, body and 
tissue weights, and body composition of mice fed a high fat diet for 90 days.   
 Control High fat 
(HF) 
HF + 1% 
Mango 















Initial 20.74 ± 1.28 20.81 ± 1.09 20.94 ± 1.18 20.82 ± 1.09 0.9929 






43.33 ± 3.85a <.0001 
Tissue weights 




1.68 ± 0.43a 0.0385 









Abdominal fat (g) 1.10 ± 0.32b 2.60 ± 0.32a 2.60 ± 0.36a 2.78 ± 0.72a <.0001 


































24.85 ± 2.33a 0.0121 
Fat mass (g) 10.04 ± 
1.79c 




21.17 ± 2.18a <.0001 






45.99 ± 2.89a <.0001 
n=15 mice/group. Mean ± S.D. Within a row, values with unlike superscript letters are 
significantly different (P ≤ 0.05) from each other. 
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Table 7:   Effects of freeze-dried mango supplementation on fasting blood glucose, 
glucose area under the curve (AUC), plasma insulin and incretin levels of mice fed a 
high fat diet for 90 days. 
 
Parameter   Control High fat 
(HF) 
HF + 1% 
Mango 






















































Glucose AUC was calculated following glucose tolerance tests in mice at the end of the 
study. n=13 mice/group.  Plasma insulin, glucagon-like peptide 1 (GLP-1) and gastric 
inhibitory peptide (GIP) were measured at the end of the study as part of an 8-plex assay 
on a bioplex multiplex reader as previously described under methods. n=8 mice/group. 
Mean ± S.D. Within a row, values with unlike superscript letters are significantly 
different (P ≤ 0.05) from each other. 
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Figure 2:  Effects of freeze-dried mango supplementation on the relative protein 
expression of the incretin receptors (a) GLP-1R and (b) GIPR in the pancreas of mice fed 














n = 6 mice/group. Data =  Mean ± SEM. Bars with unlike superscript letters are 
significantly different from each other. GLPR-1- glucagon-like peptide 1 receptor, GIPR 
– gastric inhibitory peptide receptor 
GLP-1R 
β-actin β-actin 








(b) GIPR (a) GLP-1R 
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Table 8:  Effects of freeze-dried mango supplementation on plasma and liver lipids 
of mice fed a high fat diet for 90 days. 
Lipid Control High fat 
(HF) 
HF + 1% 
Mango 
HF + 10% 
Mango 
P-value 









































NEFA (mEq/L) 0.85 ± 0.14a 0.81 ± 0.14a 0.80 ± 0.11a 0.69 ± 0.09b 0.0076 
Leptin (ng/mL) 3.23± 1.52b 12.15 ± 
3.79a 
8.62 ± 3.31a 11.84 ± 
4.71a 
<.0001 
PAI-1 (ng/mL) 0.19 ± 0.05b 0.35 ± 0.07a 0.35 ± 0.12a 0.32 ± 0.09a 0.0064 









Liver lipids (mg/g tissue) 









Total Cholesterol 3.72 ± 0.47 3.65 ± 0.74 4.00 ± 0.85 3.34 ± 0.55 0.2902 









n=15 mice/group or 8 mice/group for plasma and liver lipids, respectively. Mean ± S.D. 
Within a row, values with unlike superscript letters are significantly different (P ≤ 0.05) 
from each other. HDL- high density lipoprotein; NEFA- non-esterified fatty acids; PAI-1- 





Table 9:  Effects of mango supplementation on fecal and cecal short chain fatty acid 














Fecal SCFA (mM) 


































































Cecal SCFA (mM) 






















































n=15 mice/group or 11 mice/group for fecal and cecal SCFA, respectively. Fecal baseline samples 
were obtained from 20 mice at random (4 cages containing 4 mice/cage).  Values aremean ± S.D. 




Figure 3: Effects of freeze-dried mango supplementation on the relative mRNA 
expression of the short chain fatty acid receptor, GPR43 in the (a) ileum and (b) colon of 







n = 6 mice/group. mean ± SEM 
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Figure 4: Effects of freeze-dried mango supplementation on the relative mRNA 






















n = 6 mice/group. Mean ± SEM. Bars with unlike superscript letters are significantly 













Table 10:  Effects of freeze-dried mango supplementation on plasma cytokine levels 
in mice fed a high fat diet for 90 days 
Cytokine 
(pg/mL) 
Control HF HF + 1% M HF + 10% 
M 
P-value 




14.71 ± 1.92 24.56 ± 7.49 0.1306 













85.84 ± 7.71 107.13 ± 
32.28 
0.0862 




28.60 ± 3.53 42.70 ± 11.05 0.1527 




21.67 ± 1.51 28.80 ± 8.34 0.1597 




31.05 ± 3.69 51.63 ± 13.44 0.2183 




19.84 ± 1.65 19.31 ± 4.21 0.2296 















206.44 ± 7.65 0.6996 










































87.79 ± 15.92 0.8274 




47.54 ± 4.69 60.56 ± 15.78 0.2725 
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24.14 ± 1.14 29.84 ± 4.89 0.0869 




77.95 ± 5.99 98.92 ± 23.99 0.1140 




32.71 ± 4.34 33.68 ± 6.03 0.0731 









Plasma cytokines were measured at the end of the study with a Bioplex multiplex reader 
as previously described under methods. n=8 mice/group. Data =  Mean ± S.D. Values 
with unlike superscript letters are significantly different (P ≤ 0.05) from each other.  IL= 
Interleukin, G-CSF = Granulocyte-colony stimulating factor, IFN-γ = Interferon gamma, 
KC = Keratinocyte Chemoattractant, MCP1 = Monocyte chemoattractant protein,  MIP = 
Macrophage inflammatory protein, RANTES = Regulated on activation, normal T 







 The present study was undertaken to determine if freeze-dried mango 
supplementation can prevent the loss of beneficial gut microbiota associated with high fat 
diet. Moreover, we also investigated the effects of mango supplementation on glucose 
and lipid parameters. The findings of this study revealed that mango supplementation in 
high fat diet-fed mice prevented the loss of beneficial gut bacteria in a similar pattern to 
control without decreasing body weight or fat accumulation. It also showed a mango-
mediated modulation of gut inflammation and incretin secretion. Furthermore, 
supplementation with mango was shown to reduce dyslipidemia associated with high fat 
feeding. 
 Several studies in humans and rodent models have suggested that specific gut 
bacterial changes may play a part in the development of obesity and type 2 diabetes. For 
example, Bifidobacteria has been reported to be lower in obese [157] and type 2 diabetic 
individuals [158], with an inverse correlation between increase in fat mass in diet-
induced obese mice supplemented with inulin-type fructans [119, 159]. In addition, 
similar results have been attributed with the mucin degrader, Akkermansia muciniphila
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in a mouse model of diet-induced obesity and type 2 diabetes, as a loss of this bacterium 
induced by a high fat diet was normalized upon prebiotic feeding, leading to a reversal of 
fat mass gain and insulin resistance [118]. 
In this present study, genus level changes in the gut bacteria showed that mango 
supplementation restored Bifidobacteria and Akkermansia levels similar to control with 
the higher dose (10% mango) having the most bacterio-protective effect. Although 
mango supplementation prevented the loss of these beneficial gut bacteria due to high fat 
feeding in a similar pattern to some reported prebiotics [119], this did not translate into a 
prevention of weight gain or improved glucose tolerance. It is noteworthy that while the 
higher mango dose (10% mango) was the most effective in preventing the loss of bacteria 
due to high fat diet, these mice surprisingly had a higher body weight than other groups. 
The slightly higher caloric intake in the HF+10% mango may have contributed to their 
higher body weight.  Additionally, the increase in body weight of the HF+10% mango 
group may have been due to some species from the genus Ruminococcus which have 
been reported to possess strong energy-harvesting capabilities from starch and 
cellulolytic fibers in the colon [160] which may have been absorbed and made available 
to the host.  Moreover, some studies have also reported a failure of prebiotic feeding in 
preventing body weight gain [88, 161, 162]. A recent study using a prebiotic fiber 
constituting 1:1 ratio of inulin and oligofructose reported a lack of reduction in fat mass 
and body weight despite a dose-dependent increase in Bifidobacteria [88]. Similar results 
were reported in other studies with oligofructose supplementation [161, 162]. Results 
from the present study and others [88, 161, 162] suggest that bacterial changes at least at 
the genus level may not be the only significant factor modulating weight gain and fat 
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mass increase in obesity and its comorbidities. Therefore, metagenomic approaches such 
as shotgun sequencing, which may give an idea of upregulated or downregulated genes 
within the gut microbial genome [163] may provide an alternative to understand the link 
between mango’s effect on gut microbial changes and weight gain in obesity. However, 
this study provided evidence that mango supplementation prevented changes in the 
community structure of the gut microbiota due to high fat feeding. 
 Prebiotic feeding is known to modulate the gut microbiome and promote the 
production of short chain fatty acids (SCFA) which possess various physiological roles 
[97]. We show in this study, that mango supplementation did not only prevent the loss of 
bacteria due to high fat feeding, but also stimulated an increase in SCFA production as 
measured in both fecal and cecal samples, which suggests an increase in colonic 
fermentation with mango supplementation. In agreement with the results on bacterial 
modulation, the 10% mango dose had the most SCFA stimulatory effect as evident with a 
significant increase in acetic and butyric acid compared to the high fat group in both 
cecal and fecal samples.  
Butyrate has been established as the preferred energy source for gut epithelial 
cells [97, 164]. Importantly, colonocytes lacking butyrate may undergo autophagy [165].    
Moreover, an essential function of butyrate is the mediation of intestinal inflammation 
and promotion of mucosal tolerance [97, 166]. Butyrate improves gut tolerance to 
bacteria and antigens by promoting the differentiation of T-regulatory cells expressing 
the transcription factor, FOXp3+ [106].  Also, butyrate promotes the extra-thymic 
differentiation of T-cells in the colon into IL-10 – producing T-cells [110]. In agreement 
with increased butyrate production due to mango supplementation in this study, enhanced 
63 
 
gene expression of the anti-inflammatory cytokine, IL-10 was observed in the mango 
supplemented group compared to the high fat group.  IL-10 is vital in maintaining 
epithelial layer integrity and homeostasis [167]. A possible mechanism by which mango 
may mediate an increase in IL-10 expression may be via SCFA’s interaction with their 
receptors located in the colon mucosa and also on immune cells [109].  The SCFA 
receptor, GPR43, equally recognizes acetate, propionate and butyrate [109]. In the 
present study, a 35% increase in GPR43 expression was found in the HF+10% mango 
group compared to the HF group, although this was not statistically significant.  
On the other hand, acetate is readily absorbed into the portal blood and taken up 
by the liver in conjunction with endogenous acetate [168]. Importantly, both acetate and 
butyrate stimulate the secretion of mucin, a key component of a healthy intestinal barrier, 
thus preventing the passage bacteria or their components such as lipopolysaccharide into 
the blood [169, 170].  Therefore, it can be concluded that mango supplementation 
prevents the loss of beneficial gut bacteria, especially SCFA-producing bacteria, leading 
to a subsequent increase in SCFA production despite high fat feeding. Also, mango 
supplementation exerts gut anti-inflammatory effects via an increase in SCFA, especially 
butyric acid production. This effect of mango feeding may be important in the promotion 
of gut immune tolerance. 
 Moreover, the modulation of gut bacteria and SCFA production by mango 
supplementation may have further implications. An important link between obesity and 
cancer, especially colorectal cancer (CRC), may be obesity-induced changes in gut 
bacteria and decreased SCFA production [97]. Ou and colleagues [171] reported that low 
fiber and high fat intake is associated with increased colon cancer risk in African 
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Americans due to a reduction in gut bacteria, especially butyrate producers, and colonic 
production of butyrate. The opposite was found in rural native Africans feeding on a high 
fiber diet [171]. Several studies have shown the antitumorigenic effects of butyrate 
mainly by inhibiting histone deacetylaces (HDACs) and promoting apoptosis via other 
HDAC-independent mechanisms [102, 112, 172]. It has been shown that the anti-
inflammatory effects of butyrate in the colon is mediated via HDAC inhibition [104]. 
Thus, it is speculated that the increase in butyrate production mediated by mango 
supplementation may be vital in maintaining a healthy colon even in the face of high fat 
feeding. However, further evidence via histological studies of the colon may be needed to 
affirm the ability of mango supplementation to maintain a healthy colon despite high fat 
feeding. 
This study also investigated the effects of mango supplementation on plasma and 
hepatic lipids. Mango supplementation had a mixed effect on plasma lipids. Plasma total 
cholesterol was elevated in the high fat group, and was further elevated significantly with 
10% mango supplementation. A previous study which placed heathy volunteers on 
lactulose supplementation reported an increase in serum total cholesterol thereby 
concluding that certain types of fiber may raise serum cholesterol levels and this may be 
due to increased acetate incorporation into cholesterol in the liver [173]. In support of this 
concept, when Wolever et al. [174] gave rectal infusions of acetate to healthy subjects, an 
increase in serum acetate and cholesterol was observed. These studies present strong 
evidences that increased acetate metabolism in the liver may increase plasma cholesterol 
since acetate is a precursor of cholesterol synthesis [175]. In contrast, propionate is 
known as a strong inhibitor of acetate incorporation into cholesterol in the liver [176]. In 
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this present study, 10% mango supplementation resulted in a significant increase in both 
fecal and cecal acetate levels compared to the high fat group with only no significant 
increase observed in propionate levels. Since microbial-produced acetate and propionate 
are rapidly absorbed and metabolized in the liver [97], the elevation of plasma total 
cholesterol with 10% mango supplementation may be a result of mango’s inability to 
produce sufficient propionate levels capable of inhibiting the incorporation of acetate into 
cholesterol in the liver. 
Although mango supplementation seems to have negative effects on plasma 
cholesterol, the present study showed a dose-dependent decrease in plasma triglyceride 
levels compared to the high fat group. A similar decrease in triglyceride levels has been 
reported in healthy human volunteers supplemented with whole and fresh-cut mango 
[145]. Our study however showed that in an obese state induced by a high-fat diet, mango 
supplementation prevented an elevation in plasma triglycerides similar to control. 
Interestingly, the reduction in plasma triglyceride levels was also accompanied by 
reduction in plasma non-esterified fatty acid (NEFA) with 10% mango supplementation. 
It is noteworthy that this reduction in circulating TG and NEFA by mango 
supplementation is independent of a reduction in fat accumulation as the mango 
supplemented group had similar white adipose tissue weights as the high fat group. Since 
there were no noticeable changes in liver lipids, these results suggest a reduction in the 
lipolytic activity in the white adipose tissue which is usually elevated in high fat diet-
induced obesity state characterized by increased fat accumulation [5, 177]. A possible 
mechanism by which mango may mediate this effect may be linked to an increase in 
microbial SCFA production. Although we did not measure serum SCFA or its effect on 
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adipose tissue metabolism, the study of Ge and colleagues [178] showed that SCFAs, 
especially acetate and propionate, inhibited adipose tissue lipolysis via the activation of 
GPR43 and this effect was nullified in GPR43-deficient animals.  Therefore, mango 
supplementation reduced TG and NEFA, possibly via SCFA-mediated inhibition of 
adipose tissue lipolysis. This may be important since dyslipidemia may cause lipotoxicity 
of peripheral tissues and are linked to obesity-related complications such as 
cardiovascular occurrences [5].  
As part of understanding the effects of mango supplementation on glucose 
homeostasis, plasma concentrations of incretins (i.e., glucagon-like peptide-1, GLP-1 and 
glucose-dependent insulinotropic polypeptide, GIP) which increase insulin secretion and 
glucose sensitivity as well as enhance proliferation of β-cells, were assessed [150]. The 
present data showed that 10% mango supplementation stimulated an increase in plasma 
GLP-1 similar to the HF group without any effect on GIP. This was accompanied by a 
concomitant increase in plasma insulin only in the HF+10% mango group. This is in 
agreement with a previous study which showed an increase in plasma insulin in a GLP-1-
dependent manner in oligofructose-supplemented mice fed a high-fat diet [159]. Mango 
may act as prebiotics similar to oligofructose and increase plasma GLP-1 by increasing 
the number of enteroendocrine L-cells in the jejenum and colon [179]. The enteroinsular 
axis is known to be involved in pancreatic insulin release via incretins, in a glucose-
dependent manner [156]. Since our high fat and mango-supplemented groups had similar 
blood glucose, our data showed mango supplementation improved the efficiency of 
insulin secretion via the enteroinsular axis.  However, this increase in plasma GLP-1 and 
insulin may not have been sufficient to physiologically modulate blood glucose as we did 
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not observe any differences in glucose tolerance among the mango-supplemented and the 
high fat diet groups. 
In contrast to the data on plasma incretin l seen in this study, it was intriguing to 
note that pancreatic expression of GIP receptor was elevated by mango supplementation 
compared to the high fat group while GLP-1 receptor expression remained unchanged. 
Two factors may have contributed to this contrasting result. First, is the ability of the 
enteroinsular axis to compensate for GLP-1 inaction by upregulating the GIP-insulin axis 
[180]. Pederson and colleagues [180] showed that GLP-1R knockout mice modified the 
insulinotropic action of GLP-1 by activating the GIP component of the enteroinsular axis. 
However, a recent study concluded that the enteroinsular axis requires the concerted 
action of both incretins (GLP-1 and GIP) to maintain glucose homeostasis [156]. This 
may have been the reason that mango supplementation had no effect on glucose tolerance 
despite an increase in insulin levels. A second reason may have been our inability to 
determine the protein levels of these receptors specifically on B-islets as against the 
whole pancreas used in this study which is a limitation of our study. However, our data 
suggest that mango may be effective in improving insulin secretion by possible 
stimulation of the enteroinsular axis, although this concept needs to be further explored. 
Based on the current evidence provided in this study, future studies may focus on 
the contribution of microbial production of SCFA due to mango supplementation on 
serum SCFA and the direct impact on liver and adipose metabolism. Furthermore, the 
implication of butyrate production due to mango supplementation in this study may be 
further investigated in a model of colorectal cancer, since previous in vitro evidence has 
shown that treating colon cancer cells with mango pulp extract strongly inhibited their 
68 
 
growth and induced the expression of apoptotic markers [141]. To our knowledge, this is 
the first study to show 10% mango’s ability at increasing the abundance of the genus 
Aldercreutzia despite high fat feeding. Aldercreutzia is a recently characterized genus 
capable of producing equol, an antioxidant, from dietary isoflavonoids especially from 
soy [181, 182]. Leaning on the knowledge that mango fruit is a rich source of various 
polyphenols [135, 137, 138], it will be interesting to extensively study the possible 
impact of mango isoflavonoids on equol production and potential physiological benefits 
that may be derived from it. This may provide evidence of mango’s ability in improving 
both gut and systemic antioxidant status. 
In conclusion, this study suggest that despite the inability of mango 
supplementation in reducing body weight gain, fat accumulation and glucose intolerance 
induced by a high fat diet, it modulates gut bacteria differently from the high fat group in 
favor of the beneficial Bifidobacteria and Akkermansia, and enhanced short chain fatty 
acid production. The results also indicate that mango supplementation in mice fed a high 
fat diet mediates the reduction of plasma triglycerides and NEFA, improves insulin 
secretion possibly via the action of incretins and enhanced anti-inflammatory cytokine 
production in the gut. These results imply that mango supplementation in high fat feeding 
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